NPH 4
Latest Information Update: 10 Dec 2003
Price :
$50 *
At a glance
- Originator Asahi Breweries
- Class Antineoplastics; Coenzymes; Pterins; Small molecules
- Mechanism of Action Antioxidants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis
Most Recent Events
- 10 Dec 2003 Discontinued - Preclinical for Atherosclerosis in Japan (unspecified route)
- 13 Mar 2000 No-Development-Reported for Atherosclerosis in Japan (Unknown route)
- 03 Mar 1997 A pharmacodynamic study has been added